Effects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 study
机构：[1]Beijing University Cancer Hospital and Institute, Beijing, China.[2]Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.[3]Northern Jiangsu People's Hospital, Affiliated Hospital to Yangzhou University, Yangzhou, China.江苏省人民医院[4]The Affiliated Hospital of Jining Medical College, Jining, China.[5]The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.江苏省人民医院[6]Nantong Tumor Hospital, Nantong, China.[7]Tangshan People's Hospital, Tangshan, China.[8]Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing, China.[9]The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.[10]Fujian Provincial Hospital, Fuzhou, China.[11]Anhui Provincial Cancer Hospital, University of Science and Technology of China, Hefei, China.[12]The Affiliated Hospital of Qingdao University, Qingdao, China.[13]Suining Central Hospital, Suining, China.[14]Yunnan Cancer Hospital, Kunming, China.[15]Jiangxi Cancer Hospital, Nanchang, China.[16]Henan Cancer Hospital, Zhengzhou, China.河南省肿瘤医院[17]Harbin Medical University Cancer Hospital, Harbin, China.[18]Puyang Oilfield General Hospital, Puyang, China.[19]Inner Mongolia People's Hospital, Hohhot, China.[20]Handan Central Hospital, Handan, China.[21]Anhui Provincial Hospital, Hefei, China.[22]The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.[23]Qilu Hospital of Shandong University, Jinan, China.[24]Tianjin Cancer Hospital, Tianjin, China.[25]The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.[26]Fujian Cancer Hospital, Fuzhou, China.[27]Lishui Central Hospital, Lishui, China.[28]The First Affiliated Hospital of Anhui First University, Hefei, China.[29]Luoyang City Center Hospital, Luoyang, China.[30]Cancer Hospital Affiliated to Guangzhou Medical University, Guangzhou, China.[31]Sichuan Cancer Hospital, Chengdu, China.四川省肿瘤医院[32]Linyi People's Hospital, Linyi, China.[33]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.[34]Zhejiang Cancer Hospital, Hangzhou, China.浙江省肿瘤医院[35]Beijing University International Hospital, Beijing, China.[36]Hangzhou First People's Hospital, Hangzhou, China.[37]Innovent Biologics, Inc., Suzhou, China.
All authors reports receiving support from Innovent Biologics and Eli
Lilly for the submitted work. LS reports receiving research funding from
Innovent Biologics, Beijing Xiantong Biomedical Technology, Qilu
Pharmaceutical, ZaiLab Pharmaceutical, Beihai Kangcheng (Beijing)
Medical Technology, and Jacobio Pharmaceuticals; consultant fees from
MSD, Merck, Mingji Biopharmaceutical, Haichuang Pharmaceutical,
Herbour Biomed, and BI; honoraria from Hutchison Whampoa, Hengrui,
ZaiLab, and CSTONE pharmaceutical; and serving as a consultant
for Rongchang Pharmaceutical, ZaiLab, CSTONE Pharmaceutical, and
BMS.
第一作者机构：[1]Beijing University Cancer Hospital and Institute, Beijing, China.
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Lu Zhihao,Kong Li,Wang Buhai,et al.Effects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 study[J].Eclinicalmedicine.2024,72:102623.doi:10.1016/j.eclinm.2024.102623.
APA：
Lu Zhihao,Kong Li,Wang Buhai,Wang Junye,Liu Lianke...&Shen Lin.(2024).Effects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 study.Eclinicalmedicine,72,
MLA：
Lu Zhihao,et al."Effects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 study".Eclinicalmedicine 72.(2024):102623
医学